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Patients with monoclonal gammopathies frequently have deficient immune 
function that is condition-related. The degree of this immune deficiency 
increases with progression of disease. As a result, patients with monoclonal 
gammopathies are prone to infections that include influenza virus. Monoclonal 
gammopathy of undetermined significance (MGUS) patients with high 
monoclonal protein elicit poor IgG responses to influenza vaccination.
Methods
We therefore investigated whether the poor influenza-specific IgG response 
observed in MGUS translated to poor seroprotection rates in this cohort. 
Furthermore, we analysed the memory B cell subsets in MGUS as well as 
quantifying the influenza-specific memory B cells after administration of 
trivalent inactivated influenza vaccine. Peripheral memory B cell subsets 
were measured by flow cytometry and stimulated total and influenza-specific 
memory B cells were detected using an enzyme-linked immunospot (ELISpot) 
assay at day 0 as well as at day7- and day 28 post-vaccination.
Results
MGUS show low seroprotection rates (37%) with the Hemagglutination 
inhibition (HI) response correlating with the lower H1N1-specific IgG titers. 
The frequency of IgG+ cells in the IgD-CD27+ fraction at day 0 correlated 
with the fold increase in HI titers as well as the H1N1-specific IgG titers at day 
28 post-vaccination in HC suggesting a recall memory response. In contrast, 
the frequency of the IgG+ cells in the IgD-CD27+ fraction is decreased at 
baseline in MGUS. Furthermore, the frequency of influenza-specific IgG 
memory B cells is significantly lower post-vaccination in MGUS in comparison 
to HC, as measured by ELISpot. 
Despite the poor IgG response, MGUS elicit significant IgM and IgA 
antibody responses to influenza vaccination. However, the protective capacity 
of these two antibodies is questionable in MGUS.
Conclusion
MGUS is associated with poor IgG memory response that is likely to impair 
the long maintenance of serologic response. 




As a precursor condition to multiple myeloma (MM), MGUS does not present with 
clinical features of MM or other lymphoproliferative malignancies [1]. However, it is 
characterized by monoclonal immunoglobulin <30g/L, normal to decreased levels 
of IgG as well as by B lymphocyte percentages ranging from low to normal [2-4]. 
Additionally, there is increased susceptibility to infections in MGUS [5]. Furthermore, 
immune responses to influenza vaccination vary with M-protein levels as MGUS 
with high M-protein (>15g/L) has lower influenza-specific IgG titers which they fail 
to expand post-vaccination [6].
Influenza vaccination-induced immunity is primarily antibody based, relying on 
the activation of naïve B cells as well as the recall of memory B cells (MBCs) to rapidly 
respond upon re-encounter with antigen. Clonally expanded B cells can differentiate 
into MBCs or plasma cells that secrete antibodies at an increased rate as well as with 
higher affinity for antigen [7]. Several subsets of MBCs have been identified based 
of the expression of IgD and CD27: IgD-CD27+ classical memory switched (IgG+ or 
IgA+) cells, CD27+ unswitched memory cells that predominantly express IgD and 
IgM, but also IgM-only cells. Furthermore, IgD-CD27- (double negative (DN)) memory 
B cells have been described. Although a definite origin of the different memory B cell 
subsets remains to be established , it is proposed that isotype switched cells originate 
from germinal center (GC) reactions while IgM memory may be early emigrants from 
the GC which began participating in the GC reaction but exited before isotype 
switching [8]. Alternatively, IgM memory may develop through GC-independent 
pathways [9]. On the other hand, CD27+IgD+IgM+ cells may represent a recirculating 
fraction of marginal zone B cells [10][9]. Mutated, isotype switched DN B cells contain 
fewer somatic hypermutations in their immunoglobulin genes and have increased 
IgG3 use, further distinguishing them from their CD27+ counterparts [11].
Characteristics of the B cell response, and predominantly the nature of 
long-term B cell memory, are key determining factors of the protective capacity 
of many vaccines. These MBCs are of importance when the protective efficacy 
of a vaccine is largely determined by its ability to elicit a humoral response as in 
influenza vaccination. Indeed, parenteral vaccination with the seasonal trivalent 
inactivated vaccine induces systemic immune response on which protection is 
based. The influenza-specific circulating antibodies induced by vaccination decline 
within 6 months while longer-lasting MBCs pool remains to respond upon antigen 
re-encounter, in so doing heightening resistance to infection [12][13].
There is limited data concerning the B cell response to influenza vaccination 
in MGUS. We evaluated the peak effector responses by measuring antigen-
specific titers by both ELISA and hemagglutination inhibition test. Furthermore, 
we investigated whether the inferior response to influenza vaccination in high 
monoclonal protein MGUS was associated with alteration in total as well as antigen-




Patients were included in the study when they fulfilled the standard diagnostic 
criteria for MGUS[14]. For control purposes, sex and age matched healthy 
individuals were included parallel to the MGUS patients. Healthy controls with 
monoclonal protein in their serum were excluded. The patient characteristics have 
been previously described [6]. All participants included gave written informed 
consent in accordance with the Declaration of Helsinki. The institutional medical 
ethics committee of University Medical Centre Groningen approved the study. All 
MGUS patients and controls received an intramuscular injection of the influenza 
vaccine (Influvac, Solvay Pharmaceuticals, Netherlands) between October 2010 and 
January 2011. The vaccine, a subunit preparation of licensed 2010-2011 trivalent 
inactivated virus, contained A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) 
and B/Brisbane/60/2008. 
Cell and serum isolation
Venous blood samples were obtained at the day of vaccination (day 0), 7 days 
and 28 days post-vaccination. PBMCs were isolated using CPT vacutainer tubes 
according to manufacturer’s instructions. The PBMCs were frozen in RPMI 1640 
(Roswell Park Memorial Institute medium; Lonza, Verviers, Belgium), supplemented 
with 10% human pooled serum, 50 µg/mL gentamicin (Gibco, Paisley, UK) and 
10% dimethylsulfoxide (Merck, Germany) and then stored in liquid nitrogen until 
further analysis. Serum was separated by centrifugation and stored at -20°C until 
further analysis
Influenza-specific IgA and IgM antibodies by ELISA
The level of anti-influenza specific serum IgA and IgM antibodies against A/H1N1 
and A/H3N2 were determined by an in-house enzyme-linked immunosorbent assay 
(ELISA). ELISA plates (Costar) were coated with 1 µg/mL of A/H1N1 and A/H3N2. 
The plates were incubated overnight on a shaker. Subsequently, serum samples 
collected at day 0, day 7 and day 28 following vaccination were added to the plates 
and then serially diluted (1:4) in PBS /0.05% Tween-20 /2% BSA. To detect influenza-
specific antibodies, 1µg/ml goat anti-human IgA-HRP (Southern Biotech) or 1µg/ml 
mouse anti-human IgM-HRP (Southern Biotech) conjugate antibodies were used 
followed by incubation with 3,3’,5,5’- tetramethylbenzidine (TMB) substrate. The 
substrate reaction was stopped by adding H2SO4 (UMCG pharmacy). Absorbance 
at 450nm was read with an Emax microplate reader and antibody concentrations 
calculated by SOFTmax PRO software (Molecular Devices, Sunnyvale, USA). For a 
standard curve, a dilution series of human IgG standard, N protein (Siemens) was 
used on every plate and the antibody contents of the samples were read from the 
linear part of the sigmoid curve.




Hemagglutination Inhibition (HI) test to A/California7/2009/H1N1 was performed 
according to standard techniques as previously described [15]. The HI assay was 
performed using guinea pig erythrocytes and egg-grown influenza viruses as antigens.
Memory B cell assay
PBMCs were plated in 24-well plates at a cell concentration of 0.5x106 cells/ml was 
in RPMI 1640/10%FCS supplemented with 0.1µg/ml IL-21 ( Immunotools, Germany), 
0.1µg/ml B cell activating factor (BAFF) (PeproTech, USA) and 3.2µg/ml CpG-ODN-
2006 (InvivoGen). For negative control PBMCs were cultured in medium (RPMI 
1640, supplemented with 50 µg/mL gentamicin and 10% FCS) alone. Cells were 
subsequently incubated for 6 days at 37 °C, 5% CO2.
The samples were run in duplicates for detection of cells secreting total IgG 
antibodies as well as cells secreting TIV-specific IgG. MAIPSWU10 multiscreen 
filtration plates (Millipore, USA) were pre-wetted with 70% ethanol for 2 min and 
washed 3 times with 150 µL/well PBS (phosphate buffered saline; UMCG pharmacy). 
For coating, TIV (Influvac, Solvay Pharmaceuticals, The Netherlands) was diluted to 
1µg/ml in PBS. To detect total Ig secreting cells, wells were coated with 2.5μg/ml 
goat anti-human IgG (Bethyl Laboratories, USA). Wells with PBS only were used as 
uncoated controls. The plates were incubated overnight at 4°C. After washing the 
plates 3 times with 150 µL/well 0,01% Tween-20 (Sigma-Aldrich, USA), plates were 
blocked with 2% BSA and incubated at 37°C for 2 hours. The cultured PBMC were 
washed thoroughly before counting. The cells were subsequently resuspended in 
RPMI 1640 (+ 50 µg/mL gentamicin)/10% FCS and added to the plates in duplicates 
with 200μl cell suspension/well. The plates were incubated at 37°C for 18 hours. 
After the incubation, cells were discarded and the plates were washed with PBS 
/0,01% Tween-20 (6 × 150μl/well). Subsequently, 100 µL/well anti-human IgG-HRP 
(Bethyl Laboratories, USA) was added and plates incubated at room temperature 
for 1 hour. Unbound conjugate antibody was then washed away with PBS (3x 150µl/
well) and then developed using TMB substrate (Sanquin, NL) in the dark, at room 
temperature. To stop the reaction, the plates were washed extensively under the 
tap and dried in a light-shielded place. Finally, the number of spots per well were 
quantified with an ELISpot plate reader (A.EL.VIS, Germany). 
Immunofluorescent staining and flow cytometric analysis of B cell subsets
PBMCs were counted by the Coulter Counter (Beckman Coulter, USA) and a cell 
suspension of 2x106cells/mL was made. The following monoclonal antibodies were 
used in this study: CD19 (e-fluor 605), CD24 (PerCP- E-Fluor 710), CD27 (APC-E-Fluor 
780), CD38 (PE-Cy7), all obtained from eBioscience. IgG (FITC) from Santa Cruz 
Biotechnology, IgD (V450) and IgM (APC) were from BD Biosciences. Cells were 
incubated with directly conjugated monoclonal antibodies for 60 minutes at 4°C. 
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After staining, cells were washed with 1% BSA (Sigma-Aldrich, USA). Nine color flow 
cytometric analysis was carried out on the BD LSR II (BD Biosciences, USA) with BD 
FACSDiva Software. Cells were gated on SSC versus FSC to collect lymphocytes and 
then on CD19 cells versus SSC to gate B cells. Between 0.5 x105 and 1x 106 cells were 
collected. Further analysis for B cell subsets was done by Kaluza (Beckman Coulter, 
USA). We measured the frequency of CD19+: IgM memory (IgD+/ IgM+/ CD27+), 
switched memory B cells (IgD-/ CD27+/CD38low /CD24+) as well as CD27- memory 
(IgD-/ CD27-) and plasmablasts (IgD-/ CD27+/CD38 high/CD24-).
Statistical analysis
Data analysis was done by Graphpad Prism 5 (Graphpad software). Data are 
presented as median (range) if not otherwise stated. The Mann–Whitney test was 
used to compare groups. The Spearman rank test was used to test correlations 
between variables. Differences were considered statistically significant at p < 0.05.
RESULTS
Reduced Hemagglutination Inhibition response in MGUS
We analysed the serum Hemagglutination Inhibition titers before and 28 days after 
vaccination to evaluate whether the antibody production to one of the seasonal 
vaccine strains mirrors the responses observed by ELISA analysis. H1N1-specific 
IgG responses were established in the same MGUS cohort as for this study and 
were recently reported separately [6]. Hemagglutination inhibition titers were 
recorded according to criteria used to assess the immunogenicity of influenza 
vaccines [16]: i.e. seroprotection rates (percentage of vaccinees who achieved titers 
of ≥ 1:40 post-vaccination), seroconversion (the proportion of subjects with a 4 fold 
or greater rise in antibody titer from the prevaccination titer), Geometric mean titers 
(GMT) of HIN1 before and post-vaccination and mean fold increase (MFI) in GMT. 
The inferior response of MGUS patients observed by ELISA was also paralleled 
by HI antibody titer response. Correlations between the HI titer and serum IgG 
levels were observed at day 28 post-vaccination for healthy controls (Spearman’s 
r= 0.72; p=0.008) as well as for MGUS (Spearman’s r= 0.58; p=0.008) (Figure 1A).
No difference in HI antibody titers between controls (n=19) and MGUS (n=19) 
were detected before vaccination. In both groups, titers of influenza specific 
antibodies increased after vaccination, but responses were dampened in MGUS 
(p=0.07). The fold increase in GMT was lower in MGUS (1.3) compared to healthy 
controls (2.6) (Figure 1B). The poor increase in antibody titers therefore resulted 
in lower seroconversion rates, with only 3 (16%) MGUS patients seroconverting 
compared to 42% of healthy controls. The seroprotection rates achieved in healthy 
controls (58%) were higher than those achieved in MGUS (42%), however without 
reaching significance (p=0.06). 












Figure 1. Hemagglutination inhibition antibody responses of HC and MGUS to H1N1 
component of 2010 TIV. (A) Correlation curve for H1N1 HI titer and H1N1-specific IgG in HC 
(grey triangles) and MGUS (black squares) at day 28. (B) Geometric mean titers against H1N1 (A/
California/7/2009) at day 0 and day 28 post-vaccination for HC (n=19) and MGUS (n=19). Bars and 
error bars denote group median and interquartile range. Mean fold increase in GMT is shown as 
numerical values below. ** p<0.01; *** p<0.001. 
The frequency of TIV-specific IgG memory B cells does not increase 
following vaccination in MGUS
We have analysed the composition of the peripheral B cell pool in 5 HC and 
6 MGUS patients in which additional PBMCs were available. To further explore 
influenza vaccination-induced alterations in the B cell compartment, we compared 
circulating B cell subsets at baseline to those obtained post-vaccination (day 7 
and day 28). No statistically significant difference in the relative frequencies of 
CD27+ memory B cells and plasmablasts was observed between HC and MGUS 
at baseline (data not shown). Following vaccination, the frequencies of the B cell 
subsets remained relatively constant in HC except for plasmablasts; which showed 
a trend to an increase (but not statistically significant) at day 7 post-vaccination 
(data not shown). 
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Additionally, to investigate immunoglobulin expression on B cells, we 
evaluated the expression of IgG on IgD-CD27+ B cells. At baseline, the majority 
of the cells were of IgG isotype for both HC and MGUS. However, the frequency 
of these IgG+ cells was significantly lower in MGUS compared with HCs (p=0.05) 
(Figure 2A). The lower frequency of IgG+ cells in the IgD-CD27+ fraction in MGUS 
at baseline was due to a concomitant increase in IgM+ cells in the IgD-CD27+ 
fraction (p=0.0037). 
Furthermore, The frequency of these IgG+ cells in the CD27+ B fraction 
demonstrated positive associations with the H1N1-specific serum IgG at day 28 in 
HCs (Spearman’s r=0.7033, p=0.0073) and MGUS (spearman’s r=0.7494, p=0.002). 
Following vaccination (day 7), there was a significant decrease in the frequency of 
IgG+ IgD- CD27+cells in HC (p=0.04), however the decrease was not significant in 
MGUS. Additionally, the frequency of IgG+ in the isotype-switched CD27+ fraction 
at day 0 was positively correlated with the fold increase in hemagglutination 







Figure 2. Analysis of influenza vaccination-induced changes in IgG responses. (A)The changes 
in frequencies of IgG+ IgD- CD27+ cells in response to influenza vaccine challenge in HC and 
MGUS at day 0, day 7 and day 28. (B) The frequency of the IgG+ (CD27+ cells) correlates with 
IgG titers and the fold increase in HAI in HC. (C) IgG secreting TIV-specific memory B cells in 
HC and MGUS at day 0, day 7 and day 28 post-vaccination. The number of TIV-specific memory 
B cells was calculated as a % of total IgG secreting MBCs. *p<0.05
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Therefore, the increase in influenza-specific IgG titers is associated with higher 
numbers of total IgG+CD27+ cells.
Influenza-specific memory B cell levels are expressed as the frequency of total 
IgG-switched memory B cells (total IgG secreting cells) to normalize the data for 
differences in cell recovery as well as for changes in the overall memory B cell 
population. In order to detect the effect of influenza vaccination, we assayed the 
number of influenza-specific IgG MBCs at day 7- and day 28 post-vaccination. 
There were detectable TIV-specific IgG memory B cells at baseline for both HC 
(range 12 to 74 per 105PBMCs) and MGUS (range 0 to 106 per 105PBMCs). However, 
TIV-specific IgG memory B cells were absent in 1 MGUS patient at baseline. The 
TIV-specific IgG memory B cells averaged 4.1% (1.6- 7.2) of total IgG memory B cells 
in HC and 2.6% (0- 5.6) in MGUS. Vaccination resulted in a significant increase in the 
frequency of TIV-specific IgG memory B cells in HC (p=0.03) but not in MGUS at 
day 7 post-vaccination. This resulted in HC having significantly higher percentages 
of TIV-specific IgG memory B cells (p=0.03) that averaged 17% of total IgG memory 
B cells in comparison to 4.3% in MGUS where the frequencies of the TIV-specific 
IgG memory B cells did not show a significant increase (Figure2C). Of note is that 
the number of total IgG memory B cells at day 28 post-vaccination negatively 
correlate with monoclonal protein concentration (Spearman’s r =-0.87, p=0.03) 
(data not shown). 
MGUS patients mount significant IgA and IgM response to influenza 
vaccination 
Baseline frequencies of DN (IgD-CD27-) memory B cells as well as IgM+IgD+CD27+ 
memory B cells were comparable between HC and MGUS. However, vaccination 
resulted in an increase in the frequency of DN memory B cells at day 7 in MGUS 
(p=0.01) (Figure3A). Furthermore, IgM+ IgD+ CD27+ memory B cells were 
decreased in MGUS in response to vaccination at day 7 (p=0.01) (Figure 3B). This 
decrease at day 7 post-vaccination may indicate a difference in responding cells 
in comparison to HCs as the frequency of these cells is lower than those in HC at 
the same time-point (p=0.009).
We further examined humoral immune responses in 19 HC and 19 MGUS 
patients. We determined the H1N1 influenza-specific IgM and IgA antibody 
responses before vaccination (day 0) as well as after vaccination (day 7 and day 
28 post-vaccination). Influenza-specific IgM and IgA were detected at baseline in 
both HCs and MGUS. Vaccination resulted in a significant increase in both IgM 
(p=0.0009) and IgA (p=0.005) levels at day 7 post-vaccination in HCs with the 
levels being maintained at day 28 post-vaccination. Similarly, MGUS showed an 
increase in H1N1 influenza-specific IgM (p=0.002) (Figure 3C) and IgA (p=0.0003) 
(Figure 3D) antibody titers at day 7. However, MGUS had a trend to higher day 7 
IgM titers in comparison to HCs, though not statistically significant (p=0.07) 
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DISCUSSION
Serum titers of hemagglutination inhibiting antibodies are an universally established 
correlate of protection for influenza with seroprotection rate accepted as a proxy 
end point [17, 18]. The HI results in our study confirmed hampered vaccine-specific 
antibody responses as observed by IgG ELISA as we showed that MGUS had 
reduced HI response. Moreover, H1N1 specific IgG antibody levels correlate with 
the HI response[6]. The poor post-vaccination influenza specific IgG antibody 
levels observed in MGUS may therefore predict or mirror response to influenza 
vaccination. The seroprotection rate was lower in MGUS (37%) in comparison to 
age matched HCs (58%) suggesting that these MGUS patients are likely to be less 
protected by vaccination. 
After TIV vaccination, naïve and memory B cells that encounter antigen 





Figure 3. Effect of influenza vaccination upon peripheral B cell subset proportions and 
antibody titers. Frequencies of (A) IgD- CD27- memory B cells and (B) IgM+ IgD+ CD27+ memory 
B cells at day 0, day 7- and day 28 post-vaccination. Vaccination results in a significant increase in 
H1N1-specific IgM (C) and as well as IgA (D) in both HC and MGUS. *p<0.05; ** p<0.01; *** p<0.001.
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day 7 and subsequently decline [19]. In this study, we see a non-significant increase 
in total plasmablasts at day 7 post-vaccination in both HC and MGUS. However, we 
did not selectively look at influenza-specific antibody secreting cells to determine 
the association between the serum response and effector cells. We observed TIV 
specific MBCs in both HC and MGUS before vaccination. This is in agreement 
with other studies where pre-existing influenza specific MBCs are present in the 
circulation [20]and reflect prior vaccination or natural infection. Previous reports 
have shown that following polyclonal stimulation and ELISpot, antigen-specific IgG 
MBCs account for up to 6% of the total IgG memory at day30 post-vaccination 
[19, 20]. The responses we observed in this study were higher with TIV-specific 
MBCs making up to 29% of total IgG MBCs at day 7 and up to 14% at day 28 post-
vaccination in HCs. The differences in the immune responses observed could be 
due to the differences in the composition of the TIV vaccines in the various years. 
Furthermore, all the HC and MGUS patients in this study were vaccinated the 
previous year with A/California/2009 that was present in the current TIV. Therefore, 
a recall response was likely to be elicited. Another difference is that the previous 
studies used Staphylococcus aureus Cowan, CpG and Pokeweed mitogen [19, 21] 
as polyclonal stimuli while we used IL-21, BAFF and CpG. There may therefore be 
differences in the MBC activation efficiency between the assays. However this 
discrepancy was accounted for by measuring the frequencies of TIV-specific MBC 
in the activated total MBC population rather than as numbers of TIV-specific MBC 
per stimulated PBMCs. 
The expansion of MBCs following vaccination is enriched for antigen-specific 
cells in HC. However, vaccination did not result in a significant increase in antigen-
specific MBCs in MGUS. This poor antigen-specific memory response is likely 
to impair the maintenance of serologic response [22]. Notably, MGUS had lower 
frequencies of IgG+ IgD- CD27+ cells at baseline and influenza-specific IgG 
secreting cells are significantly lower in response to vaccination. Moreover, the 
higher levels of IgG+IgD-CD27+ cells in HC at baseline were associated with higher 
fold-increase in the HI titers but not for MGUS implying that higher frequency 
of IgG+IgD-CD27+ cells are advantageous for antibody responses. Interestingly, 
we noted that in a subset of MGUS assayed by ELISpot, high monoclonal protein 
concentration is associated with lower (total) IgG MBCs following vaccination. 
This implies that, at least in this small subset of MGUS, high monoclonal protein 
concentration is associated with a limited humoral immunologic memory that will 
potentially limit the response to influenza vaccination. 
In the IgD- CD27+ fraction, there is a decrease in the frequency of IgG+ cells that 
is compensated by an increase in IgM+ cells in MGUS at day 0 before vaccination. 
This may then limit the repertoire of IgG+ cells that is available to respond to 
vaccination. While, there is evidence of hampered IgG responses in MGUS, the 
IgM response is not negatively affected. Indeed, serum H1N1-specific IgM titers 
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in MGUS were comparable to HC as they also increased following vaccination. 
Furthermore, the change in frequencies in IgM+ (IgD+CD27+) memory B cells 
frequencies at day 7 may reflect differences in responding cells between HCs 
and MGUS. Some IgM memory B cells may differentiate into cross-reactive IgM 
antibody secreting cells leading to the increase in H1N1-specific IgM as observed. 
The rest of the IgM memory may be recruited into the secondary response to 
compensate for the hampered IgG response.
Interestingly, DN memory B cells are also substantially expanded in the 
peripheral blood of MGUS at day 7, suggesting their participation in the early 
phase of memory responses although their antigen specificity was not determined. 
Whether distinct pathways are responsible for the induction of CD27− and CD27+ 
memory B cells after antigen challenge remain debatable. However, these CD27- 
memory B cells may result from incomplete germinal center reactions therefore 
explaining their failure to acquire CD27 [23, 24]. This also explains their lower 
somatic hypermutation rates in comparison to CD27+ counterparts [25, 26]. A study 
by Moir and colleagues showed that influenza-specific IgG MBCs can be found in 
the CD27- compartment albeit at frequencies 10 times lower than in the CD27+ 
compartment of HC [25]. This would suggest that the influenza-specific response 
within the CD27−IgG+ B-cell subset would not be as effective as from its CD27+ 
counterpart.
We analyzed the relationship between memory response to influenza vaccination 
as well as the peripheral blood B cell subsets as they are easily accessible. However, 
by measuring peripheral blood B-cell subsets instead of antigen-specific B cells 
we indirectly assess the cells involved in the response to vaccination. Another 
limitation was the small group sizes of the HC and MGUS included in the different 
analyses. Nevertheless, we found several differences between the HC and MGUS 
but larger sample sizes are needed to confirm our results.
In conclusion, we have shown that MGUS elicit a significant IgM and IgA antibody 
responses to influenza vaccination despite the restricted IgG B cell response. Poor 
antigen-specific memory response in MGUS is likely to impair the maintenance of 
serologic response. The poor IgG memory response is related to high monoclonal 
protein in MGUS suggesting defect in B cell immunity.
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